Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 5/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | CMA1 | P23946 | 4/20 | 0.43 |
| ▸ | CASP3 | P42574 | 7/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.41 |
| ▸ | PADI2 | Q9Y2J8 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP9 | P55211 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606570 | 0.87 | CTSG (0.43) | CTSGCTRB1PRSS1CMA1PDE4A | |
| SCHEMBL6606162 | 0.81 | CASP3 (0.52) | CASP3PDE4APADI1PADI4PADI2 | |
| SCHEMBL8972436 | 0.80 | RAB9A (0.52) | CTSGCTRB1PRSS1CMA1 | |
| SCHEMBL6607028 | 0.79 | CTSG (0.42) | CTSGCTRB1PRSS1CMA1P2RY12 | |
| SCHEMBL6610883 | 0.74 | HPGDS (0.53) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL10977546 | 0.74 | ACE (0.49) | CTSL | |
| SCHEMBL311981 | 0.74 | CASP3 (0.43) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL15662393 | 0.74 | EPHX2 (0.42) | — | |
| SCHEMBL9087370 | 0.73 | EPHX2 (0.43) | — | |
| SCHEMBL13465351 | 0.73 | MAPT (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163208-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6632962-B2 | N-(2-carboxy-1-haloacetylethyl)arylamide derivatives as inhibitors of caspase and cellular apoptosis. | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-14 | — | — | US | disclosed |
| US-20020132833-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-09-19 | — | — | US | disclosed |
| EP-1163208-A4 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1163208-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001010383-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132833-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP7 | CTSG 216/4885CTRB1 259/4885PRSS1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.